Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation reports recurring developments as a commercial-stage biopharmaceutical company focused on hematologic malignancies. Its first-in-class telomerase inhibitor RYTELO (imetelstat) is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes with transfusion-dependent anemia.
Company updates commonly cover RYTELO net product revenue, U.S. commercialization, financial results and guidance, and continued development of imetelstat in JAK-inhibitor relapsed or refractory myelofibrosis and other hematologic malignancies. Geron news also includes investor conference participation, Nasdaq inducement grants, board appointments, executive leadership changes, and restructuring-related business updates.
Geron (Nasdaq: GERN) granted a 2,500,000-share stock option to Timothy Williams as an inducement for joining as Executive Vice President, Chief Legal Officer and Corporate Secretary.
The option was granted April 13, 2026, has a $1.73 exercise price (equal to the grant-date close), a 10-year term and vests over four years with 12.5% vesting at six months.
Geron (Nasdaq: GERN) announced on April 13, 2026 the appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary. Williams joins Geron after serving as Senior Vice President, General Counsel and Secretary at Vanda Pharmaceuticals from 2018 until March 2026.
Geron said Williams brings deep biopharma legal experience across commercial-stage companies, M&A, corporate governance, securities and compliance, and will support Geron’s strategy in hematology.
Geron (Nasdaq: GERN) will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 11:00 a.m. ET. A live audio webcast and archived audio will be available via the Investors & Media section at geron.com.
Geron (Nasdaq: GERN) appointed Patricia S. Andrews and Constantine Chinoporos to its Board of Directors on March 26, 2026.
Both appointees bring decades of biopharmaceutical leadership and commercial-stage experience and will support Geron's commercial strategy to drive growth for RYTELO.
Geron (Nasdaq: GERN) granted inducement stock options effective March 17, 2026, to six newly hired employees totaling 956,250 shares.
The options carry an exercise price of $1.62 (the closing price on the grant date), a 10-year term, and vest over four years (12.5% at six months, remainder monthly over 42 months), granted under Nasdaq Rule 5635(c)(4) and Geron’s 2018 Inducement Award Plan.
Geron (Nasdaq: GERN) reported RYTELO (imetelstat) net product revenue of $48.0M in Q4 2025 and $183.6M for full year 2025, with year-end cash and marketable securities of $401.1M. Total operating expenses for 2025 were $254.7M. For 2026 the company reiterated guidance of $220M–$240M RYTELO revenue and $230M–$240M operating expenses and expects current cash plus anticipated net revenues to fund operations.
Geron noted a 9% quarterly demand increase, ~1,300 ordering accounts, ongoing investigator and real-world trials with initial data expected H2 2026, and a workforce reduction that produced $17.0M of restructuring charges.
Geron (Nasdaq: GERN) said members of management will present at three investor events in early March 2026: TD Cowen (fireside chat) on March 2, 2026 in Boston, Barclays (fireside chat) on March 10, 2026 in Miami, and Leerink Partners in-person meetings on March 11, 2026 in Miami.
A live and archived audio webcast of each fireside chat will be available via the Investors & Media section of Geron’s website at www.geron.com.
Geron (Nasdaq: GERN) granted inducement stock options effective Feb 17, 2026, to one newly hired employee for an aggregate of 742,500 shares.
The options carry an exercise price of $1.80 per share (closing price on grant date), a 10-year term, and vest over four years with 12.5% vesting at six months and the remainder in equal monthly installments over 42 months, subject to continued employment and plan terms.
Geron (Nasdaq: GERN) will release fourth quarter and full year 2025 financial results and business highlights before market open on Wednesday, February 25, 2026. The company will host a conference call and webcast at 8:00 a.m. Eastern Time.
Live and archived audio will be available from the Investors and Media section of the company's website at www.geron.com.
Geron (Nasdaq: GERN) provided 2026 financial guidance forecasting RYTELO net product revenue of $220–$240 million and total operating expenses of $230–$240 million. The company expects top-line growth driven by focused U.S. commercial efforts and stronger second-half performance, plus year‑over‑year operating expense reduction following a strategic restructuring. Geron also noted expanded clinical evidence for RYTELO in LR‑MDS and amended its 5‑year senior secured term loan to extend the outside date for Tranche B ($75M) and Tranche C ($50M) to July 30, 2026.